NASDAQ : SBFM
Sunshine Biopharma, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 3.33 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 645.57K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 568,027 |
| Enterprise Value | -12.78M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 193,866 |
| Shares Outstanding | 193,866 |
| Shares Change (YoY) | +186.54% |
| Shares Change (QoQ) | +178.30% |
| Owned by Insiders (%) | 1.76% |
| Owned by Institutions (%) | 26.75% |
| Float | 144,992 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.02 |
| Forward PS | 0.03 |
| PB Ratio | 0.01 |
| P/TBV Ratio | 0.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.46 |
| Quick Ratio | 3.21 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -21.92% |
| Return on Assets (ROA) | -9.91% |
| Return on Invested Capital (ROIC) | -11.85% |
| Return on Capital Employed (ROCE) | -18.56% |
| Weighted Average Cost of Capital (WACC) | 5.33% |
| Revenue Per Employee | $706,935 |
| Profits Per Employee | -$116,653 |
| Employee Count | 50 |
| Asset Turnover | 1.08 |
| Inventory Turnover | 1.96 |
Taxes
| Measure | Value |
|---|
| Income Tax | 270,936 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.35 |
| 52-Week Price Change | -99.17% |
| 50-Day Moving Average | 14.16 |
| 200-Day Moving Average | 109.05 |
| Relative Strength Index (RSI) | 27.32 |
| Average Volume (20 Days) | 896,622 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 840,899 |
| Short Previous Month | 131,478 |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.06 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 35.35M |
| Gross Profit | 10.71M |
| Operating Income | -5.20M |
| Pretax Income | -5.56M |
| Net Income | -5.83M |
| EBITDA | -4.85M |
| EBIT | -5.20M |
| Loss Per Share | -$163.91 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 14.03M |
| Total Debt | 678,338 |
| Net Cash | 13.35M |
| Net Cash Per Share | $68.87 |
| Equity (Book Value) | 27.54M |
| Book Value Per Share | 230.48 |
| Working Capital | 25.05M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -5.35M |
| Capital Expenditures | -19,145 |
| Depreciation & Amortization | 349,667 |
| Net Borrowing | n/a |
| Free Cash Flow | -5.37M |
| FCF Per Share | -$27.71 |
Margins
| Measure | Value |
|---|
| Gross Margin | 30.30% |
| Operating Margin | -14.71% |
| Pretax Margin | -15.73% |
| Profit Margin | -16.50% |
| EBITDA Margin | -13.72% |
| EBIT Margin | -14.71% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -186.54% |
| Shareholder Yield | -186.54% |
| Earnings Yield | -5,594.13% |
| FCF Yield | -945.71% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 26, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.18 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |